Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 103

Similar articles for PubMed (Select 17081698)

1.

Rolipram: a specific phosphodiesterase 4 inhibitor with potential antipsychotic activity.

Kanes SJ, Tokarczyk J, Siegel SJ, Bilker W, Abel T, Kelly MP.

Neuroscience. 2007 Jan 5;144(1):239-46. Epub 2006 Nov 1.

3.

Antipsychotic profile of rolipram: efficacy in rats and reduced sensitivity in mice deficient in the phosphodiesterase-4B (PDE4B) enzyme.

Siuciak JA, Chapin DS, McCarthy SA, Martin AN.

Psychopharmacology (Berl). 2007 Jun;192(3):415-24. Epub 2007 Mar 2.

PMID:
17333137
4.

Discriminative stimulus effects of the type-4 phosphodiesterase inhibitor rolipram in rats.

Makhay MM, Houslay MD, O'Donnell JM.

Psychopharmacology (Berl). 2001 Nov;158(3):297-304.

PMID:
11713620
5.

Suppression of oro-facial movements by rolipram, a cAMP phosphodiesterase inhibitor, in rats chronically treated with haloperidol.

Sasaki H, Hashimoto K, Inada T, Fukui S, Iyo M.

Eur J Pharmacol. 1995 Aug 25;282(1-3):71-6.

PMID:
7498291
6.
7.

Inhibition of PDE3B augments PDE4 inhibitor-induced apoptosis in a subset of patients with chronic lymphocytic leukemia.

Moon E, Lee R, Near R, Weintraub L, Wolda S, Lerner A.

Clin Cancer Res. 2002 Feb;8(2):589-95.

8.

Developmental etiology for neuroanatomical and cognitive deficits in mice overexpressing Galphas, a G-protein subunit genetically linked to schizophrenia.

Kelly MP, Stein JM, Vecsey CG, Favilla C, Yang X, Bizily SF, Esposito MF, Wand G, Kanes SJ, Abel T.

Mol Psychiatry. 2009 Apr;14(4):398-415, 347. doi: 10.1038/mp.2008.124. Epub 2008 Nov 25. Erratum in: Mol Psychiatry. 2009 Dec;14(12):1145.

9.

Interaction between the antidepressant-like behavioral effects of beta adrenergic agonists and the cyclic AMP PDE inhibitor rolipram in rats.

Zhang HT, Huang Y, Mishler K, Roerig SC, O'Donnell JM.

Psychopharmacology (Berl). 2005 Oct;182(1):104-15. Epub 2005 Sep 29.

PMID:
16010541
10.

Genetics, haloperidol-induced catalepsy and haloperidol-induced changes in acoustic startle and prepulse inhibition.

McCaughran J Jr, Mahjubi E, Decena E, Hitzemann R.

Psychopharmacology (Berl). 1997 Nov;134(2):131-9.

PMID:
9399376
11.
12.
13.

Effects of the novel PDE4 inhibitors MEM1018 and MEM1091 on memory in the radial-arm maze and inhibitory avoidance tests in rats.

Zhang HT, Huang Y, Suvarna NU, Deng C, Crissman AM, Hopper AT, De Vivo M, Rose GM, O'Donnell JM.

Psychopharmacology (Berl). 2005 May;179(3):613-9. Epub 2005 Jan 26.

PMID:
15672274
15.

Inhibition of cyclic AMP phosphodiesterase (PDE4) reverses memory deficits associated with NMDA receptor antagonism.

Zhang HT, Crissman AM, Dorairaj NR, Chandler LJ, O'Donnell JM.

Neuropsychopharmacology. 2000 Aug;23(2):198-204.

16.

Relaxation of phasic contractile activity of human detrusor strips by cyclic nucleotide phosphodiesterase type 4 inhibition.

Oger S, Behr-Roussel D, Gorny D, Denys P, Lebret T, Alexandre L, Giuliano F.

Eur Urol. 2007 Mar;51(3):772-80; discussion 780-1. Epub 2006 Oct 25.

PMID:
17097801
17.

Antidepressant-like effects of PDE4 inhibitors mediated by the high-affinity rolipram binding state (HARBS) of the phosphodiesterase-4 enzyme (PDE4) in rats.

Zhang HT, Zhao Y, Huang Y, Deng C, Hopper AT, De Vivo M, Rose GM, O'Donnell JM.

Psychopharmacology (Berl). 2006 Jun;186(2):209-17. Epub 2006 Apr 4.

PMID:
16586089
18.
19.

Constitutive activation of Galphas within forebrain neurons causes deficits in sensorimotor gating because of PKA-dependent decreases in cAMP.

Kelly MP, Isiegas C, Cheung YF, Tokarczyk J, Yang X, Esposito MF, Rapoport DA, Fabian SA, Siegel SJ, Wand G, Houslay MD, Kanes SJ, Abel T.

Neuropsychopharmacology. 2007 Mar;32(3):577-88. Epub 2006 May 31.

20.

The effects of systemic NT69L, a neurotensin agonist, on baseline and drug-disrupted prepulse inhibition.

Shilling PD, Richelson E, Feifel D.

Behav Brain Res. 2003 Jul 14;143(1):7-14.

PMID:
12842291
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk